NP Paribas Leasing Solutions and Syneron Medical Announce New European Financing Framework Agreement

Brussels, Belgium, BNP Paribas Leasing Solutions and Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, are pleased to announce that the companies have signed a European framework agreement for vendor financing in the medical sector.

Following the successful implementation of vendor finance programs throughout the United States and Canada, Syneron has chosen to develop a similar program throughout Europe and has selected BNP Paribas Leasing Solutions as its key partner.

The initial European framework agreement signed by the group covers the following countries: France, Italy, Portugal, Spain, UK and Germany, with plans to expand into other countries at a future date.

The agreement will provide Syneron’s customers, which include dermatologists, plastic surgeons, family practitioners and other physicians, and medical spa professionals, with better overall choices for equipment acquisition and financial products. Through BNP Paribas Leasing Solutions, financial products such as finance leases or renting contracts, which may include variable payments schedules and irregular payments streams, are just a few of the financial products that will be available to Syneron’s customers.

The partnership between BNP Paribas Leasing Solutions and Syneron will allow both companies to benefit from the expected market growth for medical aesthetic devices. This market expansion is expected to be driven by an increasing number of consumers, growing demand for non-invasive procedures, continued technological innovation and focus on direct to consumer marketing.


About Syneron Medical Ltd.

Syneron Medical Ltd. (NASDAQ:ELOS - News) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company’s technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, thecorporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide. Additional information can be found at www.syneron.com.

BNP Paribas Leasing Solutions, far more than finance...

BNP Paribas Leasing Solutions is the brand of the business line within BNP Paribas that is specialised in leasing and rental solutions for professional equipment and in real estate assets, offered either directly to businesses and professionals or through its partners – manufacturers, publishers and their distribution channels (dealers and resellers).

With more than EUR 32.2 billion of outstandings under management and 3,600 employees located worldwide, BNP Paribas Leasing Solutions is the European leader in equipment leasing and is today the only financial institution with such a wide-ranging offer, extending from simple leasing arrangements to long term rental solutions and IT asset management contracts.

Thanks to its both global and local dimension, BNP Paribas Leasing Solutions is able to offer services and solutions that create value in 23 countries worldwide: directly in Austria, Belgium, China, France, Germany, Hungary, India (Financial Company with SREI), Italy, Luxemburg, Netherlands, Poland, Portugal, Romania, Spain, Switzerland, Turkey, United Kingdom, Ukraine ; through BNP Paribas Group entities in Algeria (El Djazaïr), Egypt (BNP Paribas Egypt), Morocco (BMCI Leasing), Tunisia (UBCI Leasing), and USA (Trinity Vendor Finance).